Evogene Ltd. Receives Nasdaq Letter
Ticker: EVGN · Form: 6-K · Filed: Mar 20, 2024 · CIK: 1574565
Sentiment: neutral
Topics: regulatory-update, nasdaq
Related Tickers: EVGN
TL;DR
Evogene got a letter from Nasdaq, details TBD.
AI Summary
On March 20, 2024, Evogene Ltd. announced it received a letter from the Nasdaq Stock Market LLC. The filing does not specify the content or implications of this letter, but it is being reported as an exhibit to this Form 6-K.
Why It Matters
Receiving a letter from Nasdaq can indicate potential issues with listing compliance or other important exchange-related matters that could affect the company's stock.
Risk Assessment
Risk Level: medium — The nature of the Nasdaq letter is unknown, which introduces uncertainty regarding potential impacts on Evogene's stock listing and valuation.
Key Players & Entities
- Evogene Ltd. (company) — The company filing the report and receiving the Nasdaq letter.
- Nasdaq Stock Market LLC (company) — The entity that sent a letter to Evogene Ltd.
- March 20, 2024 (date) — The date Evogene Ltd. announced receipt of the Nasdaq letter.
FAQ
What is the subject of the letter Evogene Ltd. received from the Nasdaq Stock Market LLC?
The filing states that Evogene Ltd. received a letter from the Nasdaq Stock Market LLC on March 20, 2024, but does not specify its subject matter.
When did Evogene Ltd. receive the letter from Nasdaq?
Evogene Ltd. announced the receipt of the letter on March 20, 2024.
Is the press release regarding the Nasdaq letter attached to this filing?
Yes, a press release announcing the receipt of the letter is attached as Exhibit 99.1 and incorporated by reference.
What is Evogene Ltd.'s principal executive office address?
Evogene Ltd.'s principal executive offices are located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Under which form does Evogene Ltd. typically file its annual reports?
Evogene Ltd. files its annual reports under cover of Form 20-F.
Filing Stats: 265 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-03-20 09:00:06
Filing Documents
- zk2431165.htm (6-K) — 10KB
- exhibit_99-1.htm (EX-99.1) — 15KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001178913-24-000995.txt ( ) — 32KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On March 20, 2024, Evogene Ltd., or Evogene, issued a press release announcing the receipt of a letter from the Nasdaq Stock Market LLC. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File Nos. 333-253300 and 333-277565) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: March 20, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release: Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification.